Agile Therapeutics (NASDAQ:AGRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRXFree Report) in a report released on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Stock Performance

Shares of AGRX stock opened at $1.51 on Wednesday. The stock has a market capitalization of $10.35 million, a P/E ratio of -0.41 and a beta of 1.58. The company has a 50 day moving average price of $1.47 and a 200 day moving average price of $0.85. Agile Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $2.63.

Agile Therapeutics (NASDAQ:AGRXGet Free Report) last issued its quarterly earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter. The company had revenue of $5.58 million for the quarter.

Hedge Funds Weigh In On Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC lifted its stake in shares of Agile Therapeutics, Inc. (NASDAQ:AGRXFree Report) by 10.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the quarter. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. Institutional investors own 10.92% of the company’s stock.

About Agile Therapeutics

(Get Free Report)

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Featured Articles

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.